Supporting the inclusion of underrepresented populations in clinical trials and real-world data studies requires a multi-faceted approach – access to real-world data sources supports decision-making to ensure diverse populations are considered proactively throughout research study phases.
This presentation done by PurpleLab and Parexel during SCOPE 2024 highlights ways to ensure studies have DEI in patient populations to meet FDA expectations and innovative ways of using healthcare data linked with deidentified SDOH attributes.
